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Abstract—Objective: To investigate primary care expenditures in the period before diagnosis of AD. Methods: In a
population-based sample of Medicare enrollees in New York City, person-level 1996 Medicare claims, summed over
primary care encounters, were examined for people who developed AD in 1997 to 1998 and those who did not. Results:
People who developed AD were more likely to use Medicare outpatient and ambulatory care 1 to 2 years before diagnosis.
Compared with respondents who did not develop AD, the excess cost for men was $1,167 (85% higher) and for women $239
(26% higher). Among elderly people 75 years in the United States, the prodromal period of AD was associated with an
excess Medicare-based primary care cost of $128.5 to $194.7 million. Conclusion: In addition to huge costs associated with
AD after diagnosis, prediagnosis costs are an unrecognized source of expenditures related to the disease.
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It is unclear if people with declining cognitive abili-
ties use primary care medical services to a greater
extent than elderly people without cognitive deficits.
Studies of medical care costs for older adults with
early AD have been inconsistent, with some studies
reporting increased utilization and others no differ-
ence. One study used the Mayo Clinic (Rochester,
MN) database to examine an incident cohort of pa-
tients with AD 1 year before diagnosis and 4 years
after diagnosis.1 This study found no differences in
inpatient or outpatient care between AD cases and
matched control subjects in either the pre- or the
postdiagnosis period. By contrast, studies of the cost
of AD in Medicare managed care have reached the
opposite conclusion.2,3
Differences in study designs make it hard to rec-
oncile these findings. Because of the high use of
nursing home care in the Mayo Clinic study, it is
possible that AD cases received primary care in this
setting. Ambulatory and outpatient care costs associ-
ated with AD in regions or medical systems with less
nursing home use may therefore be higher. By con-
trast, the managed care studies may have overesti-
mated costs associated with AD. Because these
studies did not have clinical diagnoses for ascertaining
AD cases independently of medical claims, they may
have introduced an “observation bias,” in which only
cases with the highest expenditures were identified.4
Although it is clear that AD is associated with
excess nursing home and in-home assisted living
expenditures,5-9 primarily captured in Medicaid-
reimbursed expenses, no such consensus exists for
primary care in the earliest period of the
disease.8,10-14 To investigate this issue, we examined
primary care expenditures for older adults 1 to 2
years before they received a diagnosis of AD and
compared their experience with that of elderly people
from the same cohort who never received a diagno-
sis. For comparison purposes, we also include costs
for prevalent AD cases in 1996.
Methods. Derivation of study sample. The Washington
Heights–Inwood Columbia Aging Project (WHICAP) is a
longitudinal population-based cohort, in which clinical and
epidemiologic data are collected at regular intervals and
vital status is continually updated. This stratified random
sample was drawn from Medicare enrollment files (n 
2,126) in northern Manhattan, NY, in 1992 to 1993. Sam-
pling strata for this survey included age (65 to 74, 75
years) and race–ethnicity (Hispanic, non-Hispanic black,
and non-Hispanic white). Thirty-seven systematic repli-
cate subsamples were drawn using random starts, such
that each subsample contained age and race–ethnicity
groups of equal size. The response rate for the entire sam-
ple at baseline was 62%.15,16 Analyses comparing WHICAP
participants and nonparticipants did not reveal differences
in sex or race–ethnicity.17 The Columbia University/New
York Presbyterian Institutional Review Board reviewed
and approved the WHICAP protocol.
The derivation of subjects included in analyses is shown
in figure 1. By the end of 1996, 319 (15%) subjects were
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known to have died. These people were excluded because
we matched subjects to medical claims data beginning in
January 1996 and restricted the sample to those who could
have claims throughout the whole year. We also excluded
41 subjects with other forms of dementia (stroke-related
dementia or dementia from focal effects of stroke; demen-
tia secondary to metabolic, toxic, or traumatic causes; hy-
drocephalus; or dementia with unknown cause), though we
recognize that some may be considered cases of “possible
AD.” We used Alzheimer’s Disease and Related Disorders
Association–National Institute of Neurological Disorders
and Stroke criteria to identify people with probable AD,
AD with stroke, AD with parkinsonian features, or AD
with other concomitant disease.
Excluding subjects who died before follow-up or who
had non–AD-related dementia left a sample of 1,766 who
survived 1996. Of these subjects, 258 were diagnosed with
AD in 1996 or earlier and were considered prevalent cases.
One thousand four hundred eleven never met criteria for
AD at any point throughout 1996 to 1998, and 97 met
criteria for AD for the first time in either 1997 or 1998. As
incident cases were ascertained in 1997 to 1998 and we
examined medical claims in 1996, our analyses investigate
medical care costs associated with cognitive impairment 1
to 2 years before an AD diagnosis. While an additional
small number of respondents (n  23) received an AD
diagnosis in 1999, we did not consider them prodromal
cases for this analysis. Thus, our estimates apply only to
costs 1 to 2 years before diagnosis and can be considered
conservative for this reason.
Identification of older adults who developed AD. Every
WHICAP subject completes neuropsychological testing at
each assessment interval. Respondents who met criteria
for AD were classified as either “prevalent” (subjects who
met criteria for AD at their initial assessment) or “inci-
dent” (subjects who did not meet criteria for AD at their
first visit but did so at a later visit). Although subjects
were diagnosed by the research team at different times
throughout 1997 to 1998, all subjects were assessed for
medical care costs in 1996, the same 1-year period.
Medical expenditure data. We examined Medicare out-
patient and ambulatory care [Part B] standard analytical
files for 1996, obtained from the Health Care Financing
Administration (HCFA), because these cover the domain of
primary care. The ambulatory care file (also known as the
“physician/supplier” file) covers all costs associated with
physicians, other providers, clinical lab services provided
in a physician’s office, durable medical equipment, and
related costs. The outpatient file covers all costs related to
clinic services.18 We obtained utilization and expenditure
data for all Medicare enrollees in the three zipcodes that
make up the WHICAP catchment area. We then matched
WHICAP respondents to HCFA files by social security
number and birth date and manually checked each match.
With use of Medicare data, 66.3% of the cohort had at
least one claim in either ambulatory care, outpatient, or
inpatient files. The Medicare match rate was similar
within cognitive status groups (nondemented, 65.7%; prev-
alent AD, 63.6%; prodromal AD, 75.3%; p  0.05 by 2). If
we consider Medicaid in addition to Medicare claims, the
match rate was higher: 86.5% (1,221/1,411) of the non-AD
group, 76.7% (198/258) of the prevalent AD group, and
89.1% (82/97) of the prodromal group (p  0.01). Respon-
dents in the prodromal group were significantly more
likely to have claims using the combined Medicare and
Medicaid data.
Respondents in Washington Heights–Inwood are likely
to receive primary care in both hospital outpatient and
ambulatory care settings. Hence, we computed a “primary
care” composite, which was simply the sum over all en-
counters in these two files for each subject.
Medical conditions. Research physicians and trained
research assistants elicited medical conditions (heart dis-
ease, hypertension, pulmonary disease, diabetes, arthritis,
PD, depression, or other disorders) from respondents or
proxies. The number of conditions was summed to create a
modified Charlson index.19 We established three groups (0,
1, or 2 conditions), each representing about a third of the
sample.
Analyses. Respondent-level utilization and expendi-
ture indicators were derived by summing over Medicare
encounters. For subjects who had a claim in one file (e.g.,
ambulatory care) but lacked claims in another (e.g., outpa-
tient), we assigned the subject a zero value for the latter
type of medical encounter. These subjects were clearly in
the Medicare system, and absence of a claim in such cases
can reasonably be construed as absence of a medical en-
counter. We also assigned a zero value to subjects without
claims in any of the Medicare standard analytic files and
who did not have Medicaid claims. This approach is rea-
sonable because all subjects in the cohort were originally
ascertained from Medicare enrollment files. We conducted
analyses without the latter imputation, but as results were
similar, we report only the imputed analysis.
For ambulatory and outpatient care in the cognitive
status groups, we examined any use and mean and median
expenditures in 1996, adapting the two-part model sug-
gested by Duan et al.20 Because of skew in cost distribu-
tions, we used nonparametric tests (Mann–Whitney U,
Kruskal–Wallis) to test whether median costs in groups
defined by cognitive status were significantly different.
Finally, we used expenditure data from New York City
(NYC) to estimate the aggregate US primary care cost of
cognitive impairment in the period before AD diagnosis. To
convert WHICAP expenditures into national figures, we
reweighted mean costs by race–ethnicity group to match
those of the NYC metropolitan area as a whole. We then
converted these regional costs to national estimates using
the adjusted average per capita cost (provided by HCFA),
Figure 1. Expenditure study sample: Washington
Heights–Inwood Columbia Aging Project (WHICAP).
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with appropriate age- and sex-rescaling weights. Specifi-
cally, NYC costs were multiplied by the ratio of the retro-
spective US per capita cost to the NYC cost (Part B Aged
rates: http://www.hcfa.gov/stats/hmorates/aapccflt.htm).
We obtained the proportion of elderly people in the United
States 75 years old from the US Census 200021 and used
a range of AD prevalence and incidence established in
recent meta-analyses.22,23 Because so few elderly people
younger than 75 years became incident cases, no cost esti-
mate is provided for this group. With these assumptions,
we estimated the aggregate excess primary care cost (in
1996 dollars) associated with prodromal AD projected for
the US population.
Results. Sociodemographic and vital status of WHICAP
expenditure cohort. Table 1 presents features of the cog-
nitive status groups in 1996. The groups differed signifi-
cantly in age and education; prevalent AD cases were older
and less educated. Prevalent AD cases were also more
likely to be minority. The groups did not significantly dif-
fer in total number of medical conditions. The proportion of
respondents with particular medical conditions in each of
the cognitive status groups is also shown (additional mate-
rial can be found on the Neurology Web site; go to
www.neurology.org).
Medicare expenditures in 1996. The cognitive status
groups did not significantly differ in the proportion of sub-
jects with hospitalizations in 1996 (nondemented, 14.3%;
prevalent AD, 17.2%; incident AD, 22.0%). The groups did
differ in primary care expenditures, as shown in table 2.
One to 2 years before diagnosis, people who went on to
develop AD were more likely to have an outpatient or
ambulatory care visit (82.9 vs 71.7% in nondemented and
79.8% in prevalent AD; p  0.01 by 2). Respondents who
later received AD diagnoses were also likely to have higher
primary care costs. Median costs in 1996 were $587 for
nondemented, $943 for prevalent AD, and $1,480 for pro-
dromal AD (p  0.001 by Kruskal–Wallis test for all three
groups, p  0.001 by Mann–Whitney U test for nonde-
mented vs prodromal AD).
Sex and expenditures. Separating total costs by sex
shows that the greater cost in the prodromal AD group holds
for both men and women but is considerably larger among
men (see table 2). Comparing nondemented and prodromal
AD groups, median costs were $336 and $1,738 for men (p 
0.001) and $662 and $1,389 for women (p  0.05).
Age and expenditures. Primary care costs were higher
in the prodromal group compared with people who re-
mained dementia-free, but this difference did not achieve
significance in the young–old, defined here as people
younger than 75 years (see table 2). Among elderly people











Age in 1996, y* 77.3  5.9 83.1  6.9 82.4  6.7
Education, y* 8.7  4.6 5.9  4.4 7.6  4.6
Female, %† 69.8 79.8 66.0
Race–ethnicity, %*
White 91.8 4.6 3.5
Black 77.8 15.8 6.4
Hispanic 75.9 18.4 5.6
Co-morbid
conditions, %
0 21.5 16.2 19.5
1 32.1 28.4 26.8
2 46.5 55.3 53.7
Subjects were recruited in 1992 and survived through 1996. Sub-
jects with “other” self-reported race (n  7) were excluded from
Race–ethnicity presentation. Counts of conditions were based on
a modified Charlson index.
* p 0.001, † p 0.01, by 2 or one-way analysis of variance.
WHICAP  Washington Heights–Inwood Columbia Aging
Project.
Table 2 Ambulatory and outpatient Medicare expenditures,






Full sample, n 1,221 82 198
Any primary care, %* 71.7 82.9 79.8
Primary care, median $‡ 587 1,480 943
Males, n 382 30 42
Any primary care, %† 63.9 86.7 78.6
Primary care, median $‡ 336 1,738 1,206
Females, n 839 52 156
Any primary care, % 75.2 80.1 80.1
Primary care, median $* 662 1,389 891
Age 75 y, n 521 7 23
Any primary care, % 68.3 75.0 82.6
Primary care, median $ 561 1,783 1,023
Age 75 y, n 700 75 175
Any primary care, % 74.2 84.0 79.4
Primary care, median $‡ 595 1,462 938
White, non-Hispanic, n 321 13 14
Any primary care, % 60.8 76.9 35.7
Primary care, median $ 287 1,498 0
Black, n 399 30 63
Any primary care, % 68.7 76.7 76.2
Primary care, median $* 498 1,353 902
Hispanic, n 501 39 121
Any primary care, % 81.1 89.7 86.8
Primary care, median $ 840 1,502 1,103
Primary care includes costs in outpatient and ambulatory (Part
B) files.
* p 0.05, † p 0.01, ‡ p 0.001 by 2 (any primary care) or
Mann–Whitney test (median $) for comparison of non-AD and
prodromal AD groups.
WHICAP  Washington Heights–Inwood Columbia Aging
Project.
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75 years old, the median primary care cost in the prodro-
mal AD group was $1,462 compared with $595 in the
group that remained free of dementia (p  0.001).
Race–ethnicity and expenditures. In all three race–
ethnicity groups, prodromal AD was associated with in-
creased primary care costs relative to respondents who
never met criteria for AD (see table 2). Median costs for
nondemented and prodromal AD groups were $287 and
$1,498 among whites, $498 and $1,353 among blacks, and
$840 and $1,502 among Hispanics. The small number of
whites with prevalent AD (n  14) were largely in nursing
homes and accordingly had few Medicare charges for pri-
mary care (hence the $0 median primary care charge).
Comorbid medical conditions and expenditures. Figure
2 plots primary care costs in the cognitive status groups by
number of medical conditions. Prodromal AD was associ-
ated with increased median primary care costs for respon-
dents who had one (p  0.005) or two or more (p  0.04)
conditions. Within groups defined by the presence or ab-
sence of particular medical conditions, the prodromal AD
group had higher primary care costs than the non-AD
group (additional material can be found on the Neurology
Web site; go to www.neurology.org). For example, for re-
spondents with pulmonary disease, mean primary care
costs were $2,198 for the prodromal AD group and $1,969
for the non-AD group.
Aggregate US costs of prodromal AD, elders 75 years
old. We developed estimates for the aggregate cost of pro-
dromal AD in the period before diagnosis but restricted
these estimates to people 75 years old because, as noted
earlier, few older adults younger than 75 years developed
AD. Results are shown in table 3. The mean primary care
cost (US equivalent) for men with prodromal AD in 1996
was $2,532, an excess of $1,167 (or 85%) over men who did
not develop AD. For women, the cost was $1,142, an excess
of $239 (or 26%) over women who did not develop AD.
The US Census 2000 reported 6.1 million men and 10.5
million women 75 years old and 1.2 million men and 3.0
million women were 85 years old.18 To estimate the total
cost of primary care for prodomal AD, we assumed a prev-
alence rate of 6% in the 75 to 84 age group and 20% in
people 85 years old.22 We assumed an annual AD inci-
dence of 1.1 to 1.8% for people aged 75 to 84 and 3 to 4% in
people 85 years old.22,23 With these assumptions, approx-
imately 230,000 to 345,000 people 75 years old develop
AD each year and can be considered to have prodromal
disease. Using the lower-end incidence estimate, total pri-
mary care costs for men with prodromal disease (estimated
at $2,532 per case from table 3) were $128.3 million (age
75 to 84) and $72.9 million (age 85). If these men did not
have prodromal AD, total primary care costs (estimated at
$1,365 per case) would have been $69.2 and $39.3 million.
The excess primary care expense attributable to prodromal
AD is the difference, or $92.7 million. Repeating this anal-
ysis for women, the excess primary care cost attributable
to prodromal AD is $35.8 million. The total increase in
primary care cost associated with prodromal AD is $128.5
million. With use of the higher incidence estimates, the
increase in primary care costs associated with prodromal
AD is $194.7 million.
Discussion. Respondents identified as having AD
for the first time in 1997 to 1998 were likely to have
high primary care expenditures already in 1996, 1 to
2 years before their diagnosis. This finding is
Figure 2. Median cost, 1996: AD status by number of co-
morbid conditions. Triangles  prodromal AD; stars 
prevalent AD; circles  no AD.









care cost, NYC, $*
AAPCC/USPCC US
equivalent cost, $†
Excess cost of incident
AD case in year prior to
diagnosis, $‡
Male Prevalent AD 2,967 (35) 1,972 1,309 —
Prodromal AD 2,826 (28) 3,815 2,532 1,167
No AD 1,790 (203) 2,056 1,365 —
Female Prevalent AD 1,902 (140) 987 655 —
Prodromal AD 1,854 (47) 1,720 1,142 239
No AD 1,652 (502) 1,361 903 —
* The Washington Heights–Inwood Columbia Aging Project (WHICAP) sample is skewed toward blacks (33%) and Hispanics (43%)
compared with whites (24%). Cost estimates were reweighted to reflect race–ethnicity among elders aged 75 in the NYC metropoli-
tan area as a whole, as derived from the Current Population Survey, March 2000 (blacks, 10%; Hispanics, 10%; whites, 80%).
† AAPCC  adjusted average per capita cost using age- and gender-rescaling weights. NYC costs were multiplied by (retrospective US
per capita cost [USPCC] estimates/NYC estimate) using figures for Part B Aged. Available at: http://www.hcfa.gov/stats/hmorates/
aapccflt.htm.
‡ Cost of prodromal case  cost of respondent without AD.
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strengthened by a number of features of our study
design. First, expenditure data and diagnoses were
obtained separately; thus, we were able to avoid the
observation bias that has been identified for claims-
based studies.4 Second, our results were derived from
a population-based study and hence avoid threats to
generalizability associated with samples drawn from
clinics or managed care organizations. Finally,
through use of a neuropsychological test battery and
medical and neurologic examination, we were able to
separate AD from other forms of dementia.
Why should respondents have increased primary
care expenditures in the period before an AD diagno-
sis? The increased cost does not appear to be a result
of a greater number of comorbid conditions, at least
when expressed as a simple count. When matched
for number of comorbid conditions, people who went
on to develop AD had higher primary care expendi-
tures than people who never met criteria for AD. A
limitation of this approach is that it treats each dis-
ease equally when clearly some diseases lead to more
encounters. More research on the co-occurrence of
AD and other medical conditions will be required to
clarify this issue. Increased expenditures in the absence
of at least gross differences in medical status suggest that
prodromal AD may itself increase the need for medical
care. Also, increased median costs were evident across
groups defined by race, age, and sex.
These high expenditures may be related to the
diagnostic process; that is, families utilize medical
services (primary care physician, neurologist, mem-
ory disorder clinic) as they attempt to determine
what is wrong with an elder. It is also possible that
high primary care expenditures are related to poorer
post-treatment medical outcomes in people with
early evidence of cognitive deficit who do not yet
meet criteria for AD. People who go on to receive AD
diagnoses may be less able to adhere to treatment
and medication regimens and may also fail to recog-
nize medical symptoms early. The result may be
more expensive primary care.
Additional research is required to clarify this
question. Whereas the increased risk for mortality
associated with AD is well established,24-26 people
who die with AD do not appear to die of different
causes than other people. The most frequent causes
of death, established from death certificates or
through multiple data sources (as in the National
Mortality Followback Survey), do not distinguish
people with and without AD.27 Increased primary
care expenditures associated with prodromal AD,
then, may not be due to a particular medical profile,
such as pneumonia or falls, but may instead reflect
the general medical needs of people with increasing
disability. In NYC, for example, physician evaluation
is required for Medicaid approval of personal assis-
tance care.
One potential limitation in this research is the
match rate we obtained for Medicare data. The
match rate in the WHICAP sample was 66.3%,
which is lower than that reported for older adults in
other studies, such as the National Long-Term Care
Survey.28 The WHICAP match rate should be consid-
ered in light of the predominantly minority (and im-
migrant) status of the cohort and its high Medicaid
profile.
An unexpected result in this research was the
lower use of Medicare-reimbursed primary care
among women who ultimately developed AD. This
result requires further investigation. It supports re-
cent research showing disparities between older men
and women in receipt of home care29 and suggests
that women may be better advocates for a spouse’s
health than men.
Finally, our results suggest that primary care for
people with prodromal AD is expensive. The aggre-
gate excess annual Medicare-reimbursed primary
care cost for this group, projected to the US popula-
tion 75 years old, is $128.9 to $195.5 million. Cost
estimates used for this projection were drawn from a
particular sample within one region of the United
States. For this reason, we applied adjustments to
make the sample representative of the racial–ethnic
(and hence socioeconomic) distribution of the NYC
metropolitan area as a whole and adjusted for this
regional effect. The estimate must be considered ap-
proximate, as estimates of annual AD incidence and
prevalence vary considerably. Still, the large excess
primary care cost suggests that therapies able to
delay the incidence of AD would have immediate
economic importance. It is also likely that many
other diseases are associated with excess primary
care costs in the prodromal period. These costs need
to be captured if we are to understand the total eco-
nomic impact of disease.
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